We are experiencing 4 week turn-around time in review of submissions and resubmissions. We recommend commencing this process concurrently with your ethics submission and allowing at least 8 weeks for registration to be completed from date of first submission. We currently do not have the capacity to expedite reviews.

Note also there are delays to review of updates. We appreciate your patience.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT03038100




Registration number
NCT03038100
Ethics application status
Date submitted
30/01/2017
Date registered
31/01/2017
Date last updated
9/06/2021

Titles & IDs
Public title
A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Scientific title
A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination With Paclitaxel, Carboplatin, and Bevacizumab to Patients With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Secondary ID [1] 0 0
2016-003472-52
Secondary ID [2] 0 0
YO39523
Universal Trial Number (UTN)
Trial acronym
IMagyn050
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Ovarian Cancer 0 0
Fallopian Tube Cancer 0 0
Peritoneal Neoplasms 0 0
Condition category
Condition code
Cancer 0 0 0 0
Womb (Uterine or endometrial cancer)
Cancer 0 0 0 0
Stomach

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Paclitaxel
Treatment: Drugs - Carboplatin
Treatment: Drugs - Atezolizumab
Treatment: Drugs - Bevacizumab
Treatment: Drugs - Atezolizumab Placebo

Experimental: Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab - Participants in the primary tumor-reductive surgery group will receive paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group will receive paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants will start maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.

Placebo Comparator: Placebo With Paclitaxel, Carboplatin and Bevacizumab - Participants in the primary tumor-reductive surgery group will receive paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group will receive paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants will start maintenance therapy of bevacizumab and placebo for additional 16 cycles.


Treatment: Drugs: Paclitaxel
Paclitaxel 175 milligrams per square meter (mg/m^2) IV infusion on Day 1 of each 21-day cycle

Treatment: Drugs: Carboplatin
Carboplatin at a dose to achieve a target area under the curve (AUC) of 6 milligrams per milliliter*minute (mg/mL*min) on Day 1 of each 21-day cycle for a total of 6 cycles

Treatment: Drugs: Atezolizumab
Atezolizumab 1200 mg IV infusion on Day 1 of each 21-day cycle

Treatment: Drugs: Bevacizumab
Bevacizumab 15 milligrams per kilogram (mg/kg) IV infusion as per the schedule specified in respective arms

Treatment: Drugs: Atezolizumab Placebo
Placebo matching to atezolizumab on Day 1 of each 21-day cycle

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression-Free Survival (PFS) Assessed by Investigator as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) - Intent-to-Treat (ITT) Population
Timepoint [1] 0 0
From randomization until disease progression or death from any cause (up to approximately 55 months)
Primary outcome [2] 0 0
PFS Assessed by Investigator as Per RECIST v1.1 - Programmed Death-Ligand 1 (PD-L1)-Positive Subpopulation
Timepoint [2] 0 0
From randomization until disease progression or death from any cause (up to approximately 55 months)
Primary outcome [3] 0 0
Overall Survival - ITT Population
Timepoint [3] 0 0
From randomization up to death from any cause (up to approximately 60 months)
Primary outcome [4] 0 0
Overall Survival - PD-L1-Positive Subpopulation
Timepoint [4] 0 0
From randomization up to death from any cause (up to approximately 60 months)
Secondary outcome [1] 0 0
Percentage of Participants With Objective Response (OR) Assessed by Investigator as Per RECIST v1.1 - Primary Tumor-Reductive Surgery (Having Residual Measurable Disease) Group
Timepoint [1] 0 0
From randomization until disease progression or death from any cause (up to approximately 55 months)
Secondary outcome [2] 0 0
Duration of Response Assessed by Investigator as Per RECIST v1.1 - Primary Tumor-Reductive Surgery (Having Residual Measurable Disease) Group
Timepoint [2] 0 0
From the date of first occurrence of a confirmed complete or partial response until disease progression or death from any cause (up to approximately 55 months)
Secondary outcome [3] 0 0
Percentage of Participants who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain or Bloating - Neoadjuvant Group - Clinically-meaningful improvement in patient-reported abdominal pain or bloating will be assessed using European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaires Ovarian Cancer Module 28 (EORTC QLQ-OV28) Abdominal/Gastrointestinal Symptom Scale (Items 31 and 31).
Timepoint [3] 0 0
From randomization to the end of treatment/discontinuation (up to approximately 70 weeks), and during follow-up period (up to approximately 60 months)
Secondary outcome [4] 0 0
Percentage of Participants who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group - Clinically-meaningful improvement in patient-reported function and HRQoL will be assessed using European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaires Core 30 (EORTC QLQ-C30).
Timepoint [4] 0 0
From randomization to the end of treatment/discontinuation (up to approximately 70 weeks), and during follow-up period (up to approximately 60 months)
Secondary outcome [5] 0 0
Percentage of Participants who Achieve a Clinically-Meaningful Improvement, Remain Stable or Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group - Clinically-meaningful improvement in patient-reported function and HRQoL will be assessed using EORTC QLQ-C30.
Timepoint [5] 0 0
From randomization to the end of treatment/discontinuation (up to approximately 66 weeks), and during follow-up period (up to approximately 60 months)
Secondary outcome [6] 0 0
Percentage of Participants With Adverse Events
Timepoint [6] 0 0
From randomization up to 90 days after last dose of study treatment or until initiation of new anti-cancer therapy (up to approximately 82 weeks)
Secondary outcome [7] 0 0
Maximum Serum Concentration (Cmax) of Atezolizumab - Primary surgery group: Pre-infusion (0 hr), 30 min after EOI (infusion duration=60 min) on Day 1 of Cycles 1 and 3; pre-infusion (0 hr) on Day 1 of Cycles 2, 4, 8, 16 (each cycle=21 days); end of treatment/discontinuation visit (up to approximately 66 weeks); >/=90 days after last dose (up to approximately 78 weeks) Neoadjuvant therapy group: Pre-infusion (0 hr), 30 min after EOI (infusion duration=60 min) on Day 1 of Cycles 1 and 3; pre-infusion (0 hr) on Day 1 of Cycles 2, 4 (each cycle=21 days); end of treatment/discontinuation visit (up to approximately 70 weeks); >/= 90 days after last dose (up to approximately 82 weeks)
Timepoint [7] 0 0
Pre-infusion (0 hour [hr]), 30 minutes (min) after end of infusion (EOI) on Cycle 1 Day 1(Cycle length=21 days) up to approximately 82 weeks (detailed timeframe is provided in outcome measure description)
Secondary outcome [8] 0 0
Minimum Serum Concentration (Cmin) of Atezolizumab - Primary surgery group: Pre-infusion (0 hr), 30 min after EOI (infusion duration=60 min) on Day 1 of Cycles 1 and 3; pre-infusion (0 hr) on Day 1 of Cycles 2, 4, 8, 16 (each cycle=21 days); end of treatment/discontinuation visit (up to approximately 66 weeks); >/= 90 days after last dose (up to approximately 78 weeks) Neoadjuvant therapy group: Pre-infusion (0 hr), 30 min after EOI (infusion duration=60 min) on Day 1 of Cycles 1 and 3; pre-infusion (0 hr) on Day 1 of Cycles 2, 4 (each cycle=21 days); end of treatment/discontinuation visit (up to approximately 70 weeks); >/= 90 days after last dose (up to approximately 82 weeks)
Timepoint [8] 0 0
Pre-infusion (0 hr), 30 min after EOI on Cycle 1 Day 1(Cycle length=21 days) up to approximately 82 weeks (detailed timeframe is provided in outcome measure description)
Secondary outcome [9] 0 0
Percentage of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab - Primary surgery group: Pre-infusion (0 hr) on Day 1 of Cycles 1, 2, 3, 4, 8, 16 (each cycle=21 days); end of treatment/discontinuation visit (up to approximately 66 weeks); >/= 90 days after last dose (up to approximately 78 weeks) Neoadjuvant therapy group: Pre-infusion (0 hr) on Day 1 of Cycles 1, 2, 3, 4 (each cycle=21 days); end of treatment/discontinuation visit (up to approximately 70 weeks); >/= 90 days after last dose (up to approximately 82 weeks)
Timepoint [9] 0 0
Pre-infusion (0 hr) on Cycle 1 Day 1(Cycle length=21 days) up to approximately 82 weeks (detailed timeframe is provided in outcome measure description)

Eligibility
Key inclusion criteria
- Participants receiving a histologic diagnosis of epithelial ovarian cancer (EOC),
peritoneal primary carcinoma, or fallopian tube cancer

- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

- Life expectancy greater than (>) 12 weeks

- For participants who receive therapeutic anticoagulation: stable anticoagulant regimen

- Availability of a representative formalin-fixed, paraffin-embedded (FFPE) tumor
specimen in paraffin blocks (preferred) or at least 20 unstained slides (for detailed
tissue requirements at screening)
Minimum age
18 Years
Maximum age
No limit
Gender
Females
Can healthy volunteers participate?
No
Key exclusion criteria
- Received a current diagnosis of borderline epithelial ovarian tumor (formerly tumors
of low malignant potential)

- Have recurrent invasive epithelial ovarian, fallopian tube, or primary peritoneal
cancer that was treated only with surgery (example [e.g.], participants with Stage IA
or Stage IB epithelial ovarian or fallopian tube cancers)

- Have non-epithelial ovarian tumors (e.g., germ cell tumors, sex cord stromal tumors)

- Received prior radiotherapy to any portion of the abdominal cavity or pelvis

- Received prior chemotherapy for any abdominal or pelvic tumor that include neoadjuvant
chemotherapy (NACT) for ovarian, primary peritoneal or fallopian tube cancer

- Received any biological and/or targeted therapy (including but not limited to
vaccines, antibodies, tyrosine kinase inhibitors) or hormonal therapy for management
and/or treatment of epithelial ovarian or peritoneal primary cancer

- Have synchronous primary endometrial cancer

- Have a prior history of primary endometrial cancer, except: Stage IA cancer;
superficial myometrial invasion, without lymphovascular invasion; grade less than (<)
3 or poorly differentiated subtypes, and this includes papillary serous, clear cell or
other International Federation of Gynecological Oncologists (FIGO) Grade 3 lesions

- With the exception of non-melanoma skin cancer and other specific malignancies as
noted above, other invasive malignancies with any evidence of other cancers present
within the last 5 years or previous cancer treatment that contraindicates this
protocol therapy

- Have a known hypersensitivity or allergy to biopharmaceutical agents produced in
Chinese hamster ovary cells or any component of the atezolizumab and/or bevacizumab
formulations

- Undergo major surgical procedure within 28 days prior to first bevacizumab dose, or
anticipation of the need for a major surgical procedure during the course of the study
except participants who receive NACT and will need interval surgery. This may include
but is not limited to laparotomy.

- Have prior allogeneic bone marrow transplantation or solid organ transplant

- Have any other diseases, metabolic dysfunction, physical examination finding, or
clinical laboratory finding giving reasonable suspicion of a disease or condition that
contraindicates the use of an investigational drug or that may affect the
interpretation of the results

- Have any approved or investigational anti-cancer therapy, including chemotherapy or
hormonal therapy, with exceptions: Hormone-replacement therapy or oral contraceptives

- Are administered treatment with any other investigational agent or participation in
another clinical study with anti-cancer therapeutic intent

- Have core biopsy or other minor surgical procedures within 7 days prior to the first
dose of bevacizumab

- Have known sensitivity to any component of bevacizumab

- Have known sensitivity to any component of paclitaxel

- Current treatment with anti-viral therapy for hepatitis B virus (HBV)

- History of leptomeningeal disease

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Recruitment hospital [1] 0 0
The Royal North Shore Hospital; Northern Sydney Cancer Centre - St Leonards
Recruitment hospital [2] 0 0
Peter MacCallum Cancer Center - East Melbourne
Recruitment hospital [3] 0 0
Cabrini Hospital; Cabrini Foundation - Malvern
Recruitment postcode(s) [1] 0 0
2065 - St Leonards
Recruitment postcode(s) [2] 0 0
3002 - East Melbourne
Recruitment postcode(s) [3] 0 0
3144 - Malvern
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Hawaii
Country [8] 0 0
United States of America
State/province [8] 0 0
Illinois
Country [9] 0 0
United States of America
State/province [9] 0 0
Indiana
Country [10] 0 0
United States of America
State/province [10] 0 0
Iowa
Country [11] 0 0
United States of America
State/province [11] 0 0
Kansas
Country [12] 0 0
United States of America
State/province [12] 0 0
Kentucky
Country [13] 0 0
United States of America
State/province [13] 0 0
Louisiana
Country [14] 0 0
United States of America
State/province [14] 0 0
Maine
Country [15] 0 0
United States of America
State/province [15] 0 0
Maryland
Country [16] 0 0
United States of America
State/province [16] 0 0
Massachusetts
Country [17] 0 0
United States of America
State/province [17] 0 0
Michigan
Country [18] 0 0
United States of America
State/province [18] 0 0
Minnesota
Country [19] 0 0
United States of America
State/province [19] 0 0
Mississippi
Country [20] 0 0
United States of America
State/province [20] 0 0
Missouri
Country [21] 0 0
United States of America
State/province [21] 0 0
Montana
Country [22] 0 0
United States of America
State/province [22] 0 0
Nebraska
Country [23] 0 0
United States of America
State/province [23] 0 0
Nevada
Country [24] 0 0
United States of America
State/province [24] 0 0
New Hampshire
Country [25] 0 0
United States of America
State/province [25] 0 0
New Jersey
Country [26] 0 0
United States of America
State/province [26] 0 0
New Mexico
Country [27] 0 0
United States of America
State/province [27] 0 0
New York
Country [28] 0 0
United States of America
State/province [28] 0 0
North Carolina
Country [29] 0 0
United States of America
State/province [29] 0 0
North Dakota
Country [30] 0 0
United States of America
State/province [30] 0 0
Ohio
Country [31] 0 0
United States of America
State/province [31] 0 0
Oklahoma
Country [32] 0 0
United States of America
State/province [32] 0 0
Oregon
Country [33] 0 0
United States of America
State/province [33] 0 0
Pennsylvania
Country [34] 0 0
United States of America
State/province [34] 0 0
Rhode Island
Country [35] 0 0
United States of America
State/province [35] 0 0
South Carolina
Country [36] 0 0
United States of America
State/province [36] 0 0
South Dakota
Country [37] 0 0
United States of America
State/province [37] 0 0
Texas
Country [38] 0 0
United States of America
State/province [38] 0 0
Utah
Country [39] 0 0
United States of America
State/province [39] 0 0
Virginia
Country [40] 0 0
United States of America
State/province [40] 0 0
Washington
Country [41] 0 0
United States of America
State/province [41] 0 0
Wisconsin
Country [42] 0 0
Austria
State/province [42] 0 0
Graz
Country [43] 0 0
Austria
State/province [43] 0 0
Innsbruck
Country [44] 0 0
Austria
State/province [44] 0 0
Salzburg
Country [45] 0 0
Austria
State/province [45] 0 0
Wien
Country [46] 0 0
Belgium
State/province [46] 0 0
Gent
Country [47] 0 0
Belgium
State/province [47] 0 0
Leuven
Country [48] 0 0
Belgium
State/province [48] 0 0
Wilrijk
Country [49] 0 0
Brazil
State/province [49] 0 0
RJ
Country [50] 0 0
Brazil
State/province [50] 0 0
SP
Country [51] 0 0
China
State/province [51] 0 0
Beijing City
Country [52] 0 0
China
State/province [52] 0 0
Beijing
Country [53] 0 0
China
State/province [53] 0 0
Chengdu City
Country [54] 0 0
China
State/province [54] 0 0
Chongqing
Country [55] 0 0
China
State/province [55] 0 0
Guangzhou
Country [56] 0 0
China
State/province [56] 0 0
Hangzhou
Country [57] 0 0
China
State/province [57] 0 0
Harbin
Country [58] 0 0
China
State/province [58] 0 0
Nanjing City
Country [59] 0 0
China
State/province [59] 0 0
Nanjing
Country [60] 0 0
China
State/province [60] 0 0
Nanning
Country [61] 0 0
China
State/province [61] 0 0
Shanghai City
Country [62] 0 0
China
State/province [62] 0 0
Tianjin City
Country [63] 0 0
China
State/province [63] 0 0
Zhejiang
Country [64] 0 0
China
State/province [64] 0 0
Zhengzhou
Country [65] 0 0
Czechia
State/province [65] 0 0
Olomouc
Country [66] 0 0
Czechia
State/province [66] 0 0
Ostrava-Poruba
Country [67] 0 0
Czechia
State/province [67] 0 0
Prague
Country [68] 0 0
Czechia
State/province [68] 0 0
Praha 5
Country [69] 0 0
Denmark
State/province [69] 0 0
København Ø
Country [70] 0 0
Finland
State/province [70] 0 0
Kuopio
Country [71] 0 0
Finland
State/province [71] 0 0
Tampere
Country [72] 0 0
Finland
State/province [72] 0 0
Turku
Country [73] 0 0
France
State/province [73] 0 0
Avignon
Country [74] 0 0
France
State/province [74] 0 0
Le Mans
Country [75] 0 0
France
State/province [75] 0 0
Lyon
Country [76] 0 0
France
State/province [76] 0 0
Nantes
Country [77] 0 0
France
State/province [77] 0 0
Paris
Country [78] 0 0
France
State/province [78] 0 0
Pierre Benite
Country [79] 0 0
France
State/province [79] 0 0
St Cloud
Country [80] 0 0
France
State/province [80] 0 0
Villejuif
Country [81] 0 0
Germany
State/province [81] 0 0
Berlin
Country [82] 0 0
Germany
State/province [82] 0 0
Dresden
Country [83] 0 0
Germany
State/province [83] 0 0
Essen
Country [84] 0 0
Germany
State/province [84] 0 0
Freiburg
Country [85] 0 0
Germany
State/province [85] 0 0
Greifswald
Country [86] 0 0
Germany
State/province [86] 0 0
Hamburg
Country [87] 0 0
Germany
State/province [87] 0 0
Hannover
Country [88] 0 0
Germany
State/province [88] 0 0
Heidelberg
Country [89] 0 0
Germany
State/province [89] 0 0
Konstanz
Country [90] 0 0
Germany
State/province [90] 0 0
Lübeck
Country [91] 0 0
Germany
State/province [91] 0 0
Mainz
Country [92] 0 0
Germany
State/province [92] 0 0
Muenchen
Country [93] 0 0
Germany
State/province [93] 0 0
München
Country [94] 0 0
Germany
State/province [94] 0 0
Rostock
Country [95] 0 0
Germany
State/province [95] 0 0
Ulm
Country [96] 0 0
Germany
State/province [96] 0 0
Wiesbaden
Country [97] 0 0
Greece
State/province [97] 0 0
Athens
Country [98] 0 0
Greece
State/province [98] 0 0
Ioannina
Country [99] 0 0
Greece
State/province [99] 0 0
Kifisia
Country [100] 0 0
Greece
State/province [100] 0 0
Patras
Country [101] 0 0
Greece
State/province [101] 0 0
Thessaloniki
Country [102] 0 0
Israel
State/province [102] 0 0
Hadera
Country [103] 0 0
Israel
State/province [103] 0 0
Jerusalem
Country [104] 0 0
Israel
State/province [104] 0 0
Kfar Saba
Country [105] 0 0
Israel
State/province [105] 0 0
Ramat Gan
Country [106] 0 0
Israel
State/province [106] 0 0
Rehovot
Country [107] 0 0
Italy
State/province [107] 0 0
Campania
Country [108] 0 0
Italy
State/province [108] 0 0
Emilia-Romagna
Country [109] 0 0
Italy
State/province [109] 0 0
Lazio
Country [110] 0 0
Italy
State/province [110] 0 0
Lombardia
Country [111] 0 0
Italy
State/province [111] 0 0
Piemonte
Country [112] 0 0
Italy
State/province [112] 0 0
Puglia
Country [113] 0 0
Italy
State/province [113] 0 0
Umbria
Country [114] 0 0
Italy
State/province [114] 0 0
Veneto
Country [115] 0 0
Japan
State/province [115] 0 0
Aichi
Country [116] 0 0
Japan
State/province [116] 0 0
Ehime
Country [117] 0 0
Japan
State/province [117] 0 0
Fukuoka
Country [118] 0 0
Japan
State/province [118] 0 0
Hiroshima
Country [119] 0 0
Japan
State/province [119] 0 0
Hokkaido
Country [120] 0 0
Japan
State/province [120] 0 0
Hyogo
Country [121] 0 0
Japan
State/province [121] 0 0
Iwate
Country [122] 0 0
Japan
State/province [122] 0 0
Kagoshima
Country [123] 0 0
Japan
State/province [123] 0 0
Kanagawa
Country [124] 0 0
Japan
State/province [124] 0 0
Kyoto
Country [125] 0 0
Japan
State/province [125] 0 0
Mie
Country [126] 0 0
Japan
State/province [126] 0 0
Miyagi
Country [127] 0 0
Japan
State/province [127] 0 0
Niigata
Country [128] 0 0
Japan
State/province [128] 0 0
Osaka
Country [129] 0 0
Japan
State/province [129] 0 0
Shizuoka
Country [130] 0 0
Japan
State/province [130] 0 0
Tokyo
Country [131] 0 0
Korea, Republic of
State/province [131] 0 0
Goyang-si
Country [132] 0 0
Korea, Republic of
State/province [132] 0 0
Seoul
Country [133] 0 0
Norway
State/province [133] 0 0
Oslo
Country [134] 0 0
Norway
State/province [134] 0 0
Trondheim
Country [135] 0 0
Poland
State/province [135] 0 0
Krakow
Country [136] 0 0
Poland
State/province [136] 0 0
Poznan
Country [137] 0 0
Poland
State/province [137] 0 0
Szczecin
Country [138] 0 0
Poland
State/province [138] 0 0
Warszawa
Country [139] 0 0
Russian Federation
State/province [139] 0 0
Kazan
Country [140] 0 0
Russian Federation
State/province [140] 0 0
Moscow
Country [141] 0 0
Russian Federation
State/province [141] 0 0
Saint-Petersburg
Country [142] 0 0
Spain
State/province [142] 0 0
Barcelona
Country [143] 0 0
Spain
State/province [143] 0 0
Islas Baleares
Country [144] 0 0
Spain
State/province [144] 0 0
Madrid
Country [145] 0 0
Spain
State/province [145] 0 0
Malaga
Country [146] 0 0
Spain
State/province [146] 0 0
Valencia
Country [147] 0 0
Spain
State/province [147] 0 0
Zaragoza
Country [148] 0 0
Sweden
State/province [148] 0 0
Linköping
Country [149] 0 0
Sweden
State/province [149] 0 0
Stockholm
Country [150] 0 0
Turkey
State/province [150] 0 0
Adana
Country [151] 0 0
Turkey
State/province [151] 0 0
Ankara
Country [152] 0 0
Turkey
State/province [152] 0 0
Istanbul
Country [153] 0 0
Turkey
State/province [153] 0 0
Topkapi

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Hoffmann-La Roche
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
GOG Foundation
Address [1] 0 0
Country [1] 0 0
Other collaborator category [2] 0 0
Other
Name [2] 0 0
European Network of Gynaecological Oncological Trial Groups (ENGOT)
Address [2] 0 0
Country [2] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
This is a Phase III, global, double-blind, 2-arm randomized study designed to compare the
efficacy and safety of atezolizumab + paclitaxel + carboplatin + bevacizumab versus placebo +
paclitaxel + carboplatin + bevacizumab. Study participants will have Stage 3 or 4 ovarian
cancer (OC), fallopian tube cancer (FTC), or primary peritoneal cancer (PPC) with macroscopic
residual disease postoperatively (i.e., after primary tumor reductive surgery) or who will
undergo neoadjuvant therapy followed by interval surgery.
Trial website
https://clinicaltrials.gov/show/NCT03038100
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Clinical Trials
Address 0 0
Hoffmann-La Roche
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications